Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01606735 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
A Phase 2 study of Inflammation Associated With Cataract Surgery, sponsored by ICON Bioscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 2
- Study locations
NCT01606735: Completed Phase 2 study of Inflammation Associated With Cataract Surgery, sponsored by ICON Bioscience.
NCT01606735 is a Phase 2 study of Inflammation Associated With Cataract Surgery that has completed, run by ICON Bioscience. The registered enrollment target is 172 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01606735, a Phase 2 study of Inflammation Associated With Cataract Surgery, has completed, sponsored by ICON Bioscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
Primary Outcome
This study will measure as its primary endpoint the anterior chamber cell count at Day 8 post-treatment. The proportion of patients with anterior chamber cell count = 0 at Day 8 for each dosage group will be compared.
Conditions Studied
Interventions
- DRUG IBI-10090
Study Locations (2)
California
- Inland Eye Specialists - Hemet
- California Eye Professionals - Temecula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT01606735 record still lists
NCT01606735 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher).
The record links to 1 condition, with Inflammation Associated With Cataract Surgery appearing as the primary indexed condition, and to 1 intervention - of which IBI-10090 is the first listed.
NCT01606735 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01606735 about?
NCT01606735 is a clinical study titled "Efficacy and Safety of IBI-10090 in Ocular Surgery Patients". This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
What is the current status of trial NCT01606735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2012-04. Estimated completion is 2013-03.
What conditions does trial NCT01606735 study?
This clinical trial studies the following conditions: Inflammation Associated With Cataract Surgery.
What interventions are being tested in trial NCT01606735?
The interventions under investigation include: IBI-10090 (DRUG).
Who is sponsoring clinical trial NCT01606735?
This trial is sponsored by ICON Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01606735 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01606735's enrollment target sits among peer trials
172 397th of 2000 higher than 1,603 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia